Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study.
- DOI
- 10.1186/s12885-022-10388-8
- Published
- 2023-01-19
- Container
- BMC Cancer
- Publisher
- figshare
- Open access
- yes
Credibility signals
uncertain Score 61/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-022-10388-8,
title = {Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study.},
author = {Parikh ND and Girvan A and Coulter J and Gable J and Poon JL and Kim S and Chatterjee A and Boeri M.},
year = {2023},
journal = {BMC Cancer},
doi = {10.1186/s12885-022-10388-8},
url = {https://doi.org/10.1186/s12885-022-10388-8}
}RIS
TY - JOUR TI - Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study. AU - Parikh ND AU - Girvan A AU - Coulter J AU - Gable J AU - Poon JL AU - Kim S AU - Chatterjee A AU - Boeri M. PY - 2023 JO - BMC Cancer DO - 10.1186/s12885-022-10388-8 UR - https://doi.org/10.1186/s12885-022-10388-8 ER -
APA
ND, P., A, G., J, C., J, G., JL, P., S, K., A, C., & M., B. (2023). Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study.. BMC Cancer. https://doi.org/10.1186/s12885-022-10388-8
Source records
- europe-pmc · retrieved 2026-09-26T21:04:51.280Z
- datacite · retrieved 2026-09-26T21:04:51.267Z
- datacite · retrieved 2026-09-26T21:04:51.267Z
- doaj · retrieved 2026-09-26T21:04:51.277Z